Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Protocol H8D-MC-EMBH PPAR Alpha (LY518674): a Phase 2 Dose-Response Study to Evaluate the Blood Pressure-Lowering Effect in Essential Hypertension

NCT00374855 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT00374855
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00374855 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Protocol H8D-MC-EMBH PPAR Alpha (LY518674): a Phase 2 Dose-Response Study to Evaluate the Blood Pressure-Lowering Effect in Essential Hypertension
Lead sponsor
Eli Lilly and Company
Phase
Phase 2
Overall status
Completed
Start date
September 30, 2006
Completion date
November 30, 2006
Enrollment
153
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

mild hypertension